Cutaneous melanoma is a type of cancer with an inherent potential for lymph node colonization, which is generally preceded by neolymphangiogenesis . Here, we exploit this inducibility of VEGFR3 to engineer mouse melanoma models for whole-body imaging of metastasis generated by human cells, clinical biopsies or endogenously deregulated oncogenic pathways. This strategy revealed early induction of distal pre-metastatic niches uncoupled from lymphangiogenesis at primary lesions. Analyses of the melanoma secretome and validation in clinical specimens showed that the heparin-binding factor midkine is a systemic inducer of neo-lymphangiogenesis that defines patient prognosis. This role of midkine was linked to a paracrine activation of the mTOR pathway in lymphatic endothelial cells. These data support the use of VEGFR3 reporter mice as a 'MetAlert' discovery platform for drivers and inhibitors of metastasis.
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Cutaneous melanoma is a type of cancer with an inherent potential for lymph node colonization, which is generally preceded by neolymphangiogenesis [1] [2] [3] . However, sentinel lymph node removal does not necessarily extend the overall survival of patients with melanoma 4, 5 . Moreover, lymphatic vessels collapse and become dysfunctional as melanomas progress 6, 7 . Therefore, it is unclear whether (and how) lymphangiogenesis contributes to visceral metastasis. Soluble and vesicle-associated proteins secreted by tumours and/or their stroma have been proposed to condition pre-metastatic sites in patients with melanoma [8] [9] [10] [11] [12] [13] [14] . Still, the identities and prognostic value of lymphangiogenic mediators remain unclear 2, 14 . Moreover, our understanding of lymphangiogenesis (in melanomas and other tumour types) is limited by the paucity of mouse models for live imaging of distal pre-metastatic niches 15 . Injectable lymphatic tracers have been developed 7 , but their limited diffusion precludes whole-body imaging at visceral sites 16 . Vascular endothelial growth factor receptor 3 (VEGFR3) is an attractive 'lymphoreporter' 17 because its expression is strongly downregulated in normal adult lymphatic endothelial cells, but is activated in pathological situations such as inflammation and cancer 17, 18 . Here, we exploit this inducibility of VEGFR3 to engineer mouse melanoma models for whole-body imaging of metastasis generated by human cells, clinical biopsies or endogenously deregulated oncogenic pathways. This strategy revealed early induction of distal pre-metastatic niches uncoupled from lymphangiogenesis at primary lesions. Analyses of the melanoma secretome and validation in clinical specimens showed that the heparin-binding factor midkine is a systemic inducer of neo-lymphangiogenesis that defines patient prognosis. This role of midkine was linked to a paracrine activation of the mTOR pathway in lymphatic endothelial cells. These data support the use of VEGFR3 reporter mice as a 'MetAlert' discovery platform for drivers and inhibitors of metastasis.
To generate animal models for whole-body imaging of neolymphangiogenesis in melanoma progression, we used Flt4 tm1.1Sgo (Vegfr3 EGFPLUC ) mice 17 , a knock-in system in which an EGFP-luciferase fusion cassette is coupled to the transcription of Vegfr3 (Fig. 1a) . These VEGFR3 reporter mice (herein referred to as Vegfr3
Luc for simplicity) were crossed with immune-deficient Foxn1 nu (nu/nu) mice and used as hosts for human melanoma cell lines and patient-derived xenografts. immune-competent mouse strains 19 were performed to monitor benign nevi or malignant melanomas. These genetically engineered mouse models (GEMM) were maintained in black-coat or albino backgrounds to characterize pigmented or amelanotic lesions (Fig. 1a) .
Crosses to
A panel of nine melanoma cell lines with different levels of VEGFC, a main known driver of lymphangiogenesis 3 , were used to generate subcutaneous xenografts in Vegfr3
Luc nu/nu mice (Extended Data Fig. 1a, b ). This set of cell lines also recapitulated the most frequent melanoma-associated alterations in BRAF, NRAS, PTEN and p53 (Supplementary Table 1 ). Before implantation, cells were transduced with mCherry for dual fluorescence-bioluminescence imaging of tumour growth and subsequent emission of VEGFR3-associated luciferase (V3-Luc), respectively (see examples in Fig. 1b) . Histological staining for VEGFR3 in Lyve1-positive lymphatic endothelial cells (LEC) confirmed neo-lymphangiogenesis (see Fig. 1c for examples in the skin, and Extended Data Figs 1c-e, for lymph nodes, spleen and lungs, respectively).
We identified four major patterns of tumour-driven neolymphangiogenesis: with no V3-Luc at any site (pattern I); restricted to the primary tumour (II); occurring locally and distally (III); and, unexpectedly, without or with highly delayed tumoural V3-Luc but with potent systemic emission (IV) (Fig. 1d , e, Extended Data Fig. 2a-c and Supplementary Information). Only patterns III and IV (those including distal V3-Luc) were found to substantially increase lymphatic vessel density at lymph nodes and to result in efficient nodal metastasis (Extended Data Fig. 2c-f ). These patterns did not correlate with BRAF, NRAS, p53 or PTEN status (not shown). Moreover, tumoural VEGFC was neither sufficient nor essential for the activation of distal V3-Luc and nodal metastases ( Fig. 1a and Extended Data Fig. 2 , where VEGFC-positive cell lines are labelled in green). Patient-derived xenografts from human skin metastases further confirmed early and systemic induction of V3-Luc uncoupled from prior tumoural lymphangiogenesis (Extended Data Fig. 3a, b) . Systemic V3-Luc was also obvious in GEMM melanomas (but not in nevi), in both pigmented and amelanotic backgrounds (Extended Data Fig. 3c-e) .
Tumour burden estimated by quantitative RT-PCR at different anatomical locations and time points after tumour cell implantation revealed significant systemic activation of V3-Luc prior to tumour cell colonization (see black dots in Fig. 2a , b for quantitative analyses in lymph nodes and lungs; P < 0.01 and P < 0.001, respectively). These data support the idea that V3-Luc positive sites represent pre-metastatic niches. V3-Luc imaging was then analysed before and after surgical removal of xenografts of human melanoma cells (SK-Mel-147; Fig. 2c ) or GEMM melanomas (Extended Data Fig. 4) . In both cases, excision of primary lesions led to a marked reduction in V3-Luc. Metastatic relapses were found at later time points (involving skin, lymph node and lung metastases) and were invariably preceded by V3-Luc emission (Fig. 2d) . Therefore, early systemic luciferase emission in Vegfr3
Luc mice reflects long-distance signals fuelled by the primary lesions.
Proteomic analyses were then performed to identify tumour-secreted drivers of distal lymphangiogenesis and metastasis. Exosome cargo was defined using label-free liquid chromatography-mass spectrometry (Fig. 3a) in representative examples of the four V3-Luc emission patterns described above. Candidate drivers were filtered for statistical significance, selective expression in cell lines with systemic V3-Luc emission, no previous lymphangiogenic roles and no links to melanoma (see Methods). The top scoring candidate was the heparin-binding factor midkine (MDK; marked in blue in the volcano plots of Fig. 3b ; see additional secreted proteins in Supplementary Table 2) . We found it particularly encouraging that MDK is secreted by other cancer types [20] [21] [22] [23] and has been proposed to mediate metastasis by its mitogenic, proinflammatory and angiogenic functions 20, [23] [24] [25] , but has no connection to lymphovascular expansion.
Immunohistochemical analyses confirmed that MDK was expressed in highly metastatic melanoma xenografts ( Fig. 3c and Extended Data Fig. 5a ). Importantly, although we had found MDK as an exosome cargo, enzyme-linked immunosorbent assay (ELISA) and 
Figure 1 | Vegfr3
Luc reporter mice for wholebody analysis of benign and malignant melanocytic lesions. a, Vegfr3
Luc mouse models used in this study, with the five strains generated indicated with numbers in circles. Here and in all corresponding figure panels * P ≤ 0.05, * * P ≤ 0.01, ***P ≤ 0.001. immunoblotting after exosome depletion showed 40-60-fold higher expression of MDK in the soluble fraction of aggressive melanoma cells (Extended Data Fig. 5b ). Therefore we proceeded with the analysis of soluble MDK in the secretome of melanoma cells.
Loss-and gain-of-function studies were performed to manipulate the endogenous levels of MDK. For loss-of-function tests, we used five short hairpin RNAs (shRNAs). Of those, quantitative PCR with reverse transcription (qRT-PCR) and ELISA identified shMDK(1) and shMDK(5) as the most potent blockers of MDK expression and secretion (Extended Data Fig. 5c, d ). None of these shRNAs affected intracellular levels of VEGFC or VEGFD mRNA (Extended Data Fig. 5e ). Moreover, MDK depletion did not significantly affect the growth or blood vessel density of melanoma xenografts (Extended Data Fig. 5f, g ). This is in contrast to the mitogenic 20,24 and angiogenic roles of MDK in other settings 26, 27 . Instead, in melanoma xenografts, MDK shRNAs decreased lymphatic vessel density (LVD) and reduced tumoural V3-Luc (Extended Data Fig. 5h, i and Fig. 3e, respectively) . Nevertheless, the most obvious effect of MDK downregulation was found systemically, with marked inhibition of bioluminescence and metastasis to lymph nodes ( Fig. 3d-g ) and visceral organs (Fig. 3h) . In turn, gain of function (restoring MDK expression; Extended Data Fig. 6a ) was sufficient to convert the non-lymphangiogenic WM164 cell line into a potent inducer of systemic V3-Luc (Fig. 3i, j) , favoring metastatsis to lymph nodes ( Fig. 3k) and distal sites (shown for lungs in Fig. 3l and Extended Data Fig. 6b ), without affecting VEGFC or VEGFD mRNA, or the growth and vascularization of the cutaneous lesions (Extended Data  Fig. 6c, d and data not shown).
In further support of a pro-lymphangiogenic role for MDK, ectopic expression of this protein in LEC induced Vegfr3 mRNA (see qRT-PCR analyses in Extended Data Fig. 6e ). Moreover, conditioned medium from MDK-expressing melanoma cells enhanced LEC proliferation, whereas medium from cells with loss of MDK function had an inhibitory effect (Extended Data Fig. 6f, g ). In addition, confocal immunofluorescence in MDK gain-of-function experiments demonstrated that MDK accumulated at sites of nodal neolymphangiogenesis in vivo (see Fig. 3m for colocalization with Lyve1-LEC in lymph nodes, Conceptually, increased lymphatic vessel density would not be expected to promote metastasis per se, unless it were coupled to effective intra-or extravasation of tumour cells. Time-lapse videomicroscopy revealed that incubation of LEC with MDK increased the adhesion and transmigration of WM164 and SK-Mel-147 cells (Supplementary Videos 1 and 2; Extended Data Fig. 7a-c) . The ability of MDK shRNA to inhibit the intravasation of melanoma cells through LEC was confirmed histologically (Extended Data Fig. 7d, e) . Moreover, the pro-metastatic ability of MDK was further supported by intravital imaging of melanoma cells invading the subcapsular sinus at sentinel lymph nodes (Extended Data Fig. 8 ; see Methods).
RNA sequencing (RNA-seq) was performed in LECs incubated with conditioned medium from gain-and loss-of-function studies to identify downstream effectors of MDK (Fig. 4a) . Genes that were regulated in opposing directions by gain or loss of MDK function are shown in heat maps in Fig. 4b . Ingenuity pathway analyses (IPA) and gene set enrichment analyses (GSEA) identified multiple cancer hallmarks and oncogenic signatures as putative downstream effectors of MDK (Supplementary Tables 3, 4 ). These included the mTOR pathway as one of the most enriched MDK-associated signalling cascades (Fig. 4b, c) .
The mTOR pathway was intriguing because, in addition to its longknown contribution to tumour cell growth and motility, it has been found to modulate lymphangiogenesis 28, 29 , although with no previous link to MDK. The conditioned medium of MDK-expressing melanoma cells promoted the phosphorylation of the mTOR target RPS6 in LEC (Fig. 4d) . MDK-induced phosphorylation of RPS6 was accompanied by induction of VEGFR3 expression ( Fig. 4e ) and LEC sprouting (Extended Data Fig. 9a ). The dependency on MDK and mTOR of these LEC-associated effects was confirmed by using conditioned medium from MDK-depleted cells and the mTOR inhibitors torin 1 and rapamycin ( Fig. 4e and Extended Data Fig. 9b, c) . Moreover, histological analyses of xenografts in Vegfr3
Luc mice showed activation of the mTOR pathway (phosphorylation of RPS6) in vivo at sites of MDK-induced neolymphangiogenesis (Extended Data Fig. 9d ). Together, these results identify a functional role of MDK in melanoma as a mechanistic link between two key pro-tumorigenic processes: neolymphangiogenesis and mTOR signalling.
Analysis of a retrospective series of human benign nevi and melanomas confirmed tumour-associated expression of MDK (Fig. 4f, g and Extended Data Fig. 10a, b) . Moreover, an independent series of sentinel lymph nodes from 62 patients with stage II-III melanoma showed that patients with high nodal MDK expression (Extended Data Fig. 10c ) had significantly worse disease-free survival (DFS) than patients with low nodal MDK expression (P = 0.0034; Fig. 4h ), even when they had tumour-negative sentinel lymph nodes (P = 0.0243; Extended Data Fig. 10d ). Multivariate analyses confirmed that the correlation between high MDK expression and reduced DFS was independent of the age and gender of the patient and, importantly, of the thickness (Breslow depth) of the primary lesion (Extended Data Fig. 10e ). The immunocompetent and immunodeficient VEGFR3-lymphoreporter mouse models of melanoma generated in this study have uncovered distinct patterns of metastatic progression that can bypass the requirement for intra-or peri-tumoural lymphangiogenesis. Live imaging coupled with loss-and gain-of-function studies revealed that MDK influences LEC via paracrine effects of the mTOR pathway on VEGFR3 expression (Extended Data Fig. 10f) . Moreover, the physiological relevance of MDK was validated by multivariate analysis of disease-free survival of patients with melanoma. We anticipate that the genome-wide proteomic RNA-seq data presented here, showing modulation of pro-inflammatory molecules in melanoma cells and LEC, may open new areas of investigation. For example, the accumulation of MDK at the lymph node subcapsular sinus (Extended Data  Figs 8, 10c ) may affect the function of this structure as a physical and immunological barrier to tumour cell dissemination 30 . In this context, it will be interesting to determine whether MDK (and mTOR) cooperate with other factors that are enriched in the secretome of metastatic melanoma cells. As the Vegfr3
Luc reporters in this study are not limited to melanoma, they may represent a versatile 'metastasis-alert' platform for gene discovery and drug testing in a broad spectrum of malignant diseases.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. ) and
Vegfr3
Luc nu/nu mouse models (Strain 1), contributed to experimental design, discussed data and revised the manuscript. I.M.-C. generated the Vegfr3 19 and Pten tm2Mak (ref. 32 ). Albino and black-coated animals were bred independently. Mice were genotyped as previously described 19, 31, 32 . Nevi and melanomas in the Tyr::CreERT2 strains were induced in 14-week-old female mice by topical treatment with 5 μ l of 5 mM 4-hydroxy-tamoxifen as previously described 19 . Animals were maintained in an inbred background and genotyped as described by the manufacturers. All experiments with mice were performed in accordance with protocols approved by the Institutional Ethics Committee of the CNIO and the Instituto de Salud Carlos III (see below for maximum size of the tumour lesions). No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Cell culture. Human primary melanocytes were isolated from neonatal foreskins 33 and maintained in medium 254 supplemented with melanocyte growth factors (HMG-1) containing 10 ng ml −1 phorbol 12-myristate 13-acetate (Invitrogen). Melanoma cells 34 were cultured in DMEM (Invitrogen) supplemented with 10% FBS, 100 μ g ml −1 penicillin and 100 μ g ml −1 streptomycin. See Supplementary Table 1 for a list of melanoma cells used and their genetic backgrounds. Human lymph node endothelial cells (HLEC) Innoprot (Derio) were cultivated in Clonetics EGM-2 MV BulletKit (Lonza) following the manufacturer's instructions. HLEC were used within six passages in culture. All the melanoma cell lines were authenticated using GenePrint 10 Loci Service and all the cell lines were routinely tested for mycoplasma contamination. Gene silencing and overexpression by lentiviral transduction. MDK silencing was performed by lentiviral-driven expression of shRNAs, with pLKO-constructs purchased from Sigma: MDK-sh1 (Clone ID NM_002391.3-505s21c1); MDK-sh2 (238s21c1); MDK-sh3 (337s21c1); MDK-sh4 (421s21c1); MDK-sh5 (621s21c1). Non-target shRNA (CAACAAGATGAAGAGCACCAA) was used as control. Infected cells were selected by incubation with puromycin (1 μ g ml ) and MDK downregulation was determined by protein immunoblotting, ELISA or qRT-PCR (see below). For the overexpression of human MDK, ORF lentiviral expression vector pReceiver-Lv105-A0792 (MDK) and the corresponding empty vector were purchased from Genecopoeia. Viruses were produced in 293FT cells and infections were performed as previously described 35 . When indicated, cells were stably infected with mCherry pLV-puro lentiviral vectors as described 35 . Non-invasive imaging of tumour growth and neolymphangiogenesis in vivo by bioluminescence and fluorescence optical imaging. To analyse xenografts from human melanoma cells, subcutaneous implantations were performed with mCherrylabelled cells (1-5 × 10 6 cells) into the flanks of 14-week old Vegfr3 Luc nu/nu mice. Patient-derived xenographs (PDX) were generated from freshly isolated biopsies of skin metastases. Tumour growth was monitored every 2 d by caliper measurement of the two orthogonal large and small external diameters (a, b), and volume was estimated using the formula V = a × b 2 × 0.52. Non-invasive imaging of mCherry fluorescence or V3-Luc bioluminiscence was performed using an IVIS-SPECTRUM imaging system (PerkinElmer). Mice were anaesthetized with isoflurane and injected intraperitoneally with 150 mg kg −1 luciferin (PerkinElmer). Sequential images were obtained after luciferin injection and the maximum light emission was determined for each mouse as previously described 17 . Photons emitted from specific regions were quantified using Living Image software (Caliper Life Sciences). In vivo dual fluorescence/bioluminescence imaging was performed at different time points after cell implantation, until tumours reached an average final size of 1,500 mm 3 or an average diameter of 1.5 cm (set to follow ethical procedures for humane handling of animals 36 ). Post hoc analyses were then performed in representative cell lines for in-depth quantification of V3-Luc emission at the tumour, inguinal and brachial lymph nodes and in visceral organs (spleen, liver and lung), corresponding to animals with defined tumour sizes (i.e. 0, 250, 500, 1,000 and 1,500 mm Luc nu/nu mice were as follows: pattern I (for example, WM164) corresponded to the expected behaviour of xenografts expressing low levels of VEGFC: namely, no signs of V3-Luc emission at any anatomical site (Fig. 1d, e, top panels) , no altered lymphatic density (Extended Data Fig. 2c ) and infrequent metastatic colonization of sentinel lymph nodes, as determined by fluorescence-based imaging (Extended Data Fig. 2d ). Pattern II was exemplified by WM35, a VEGFC-expressing cell line (Extended Data Fig. 1c, d) . In this case, potent induction of V3-Luc was detected at the tumour site, but there was minor distal luciferase emission and no significant nodal metastatic potential (second row in Fig. 1d, e; Extended Data Fig. 2c, d ). Pattern III was represented by metastatic cell lines (WM902B, UACC62, SK-Mel-103 and SK-Mel-147) with local and distal activation of Vegfr3 Luc (third row in Fig. 1c, d ; Extended Data Fig. 2a, b ) and nodal metastases (Extended Data Fig. 2d ), but with no correlation to VEGFC mRNA expression (Extended Data Fig. 1c) . Pattern IV corresponded to cell lines (WM115, 451LU and SK-Mel-28) that did not express significant VEGFC and induced minimal or highly delayed tumoural bioluminescence, but still promoted marked V3-Luc emission at lymph nodes and subsequently at spleen, liver and lung (bottom row in Fig. 1d, e; Extended Data Fig. 2d-f) .
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MethOdS
Mouse breeding and induction of nevi and melanomas in
Immunocompetent Vegfr3 Luc -GEMM nevi and melanoma were imaged following similar techniques and procedures as for Vegfr3
Luc nu/nu mice, with animals killed when tumour areas covered a maximum 700 mm 2 of the mice. Sample sizes were chosen to ensure statistical significance. No randomization or blind analyses were performed. All experiments with mice were performed in accordance with protocols approved by the Institutional Ethics Committee of the CNIO and the Instituto de Salud Carlos III 36 . Protein immunoblotting and histological analyses of gene expression in mouse tumours. For western blotting, primary and secondary antibodies were diluted in 5% milk TBS-T incubated overnight at 4 °C or for 1 h at room temperature. Primary antibodies used were: MDK (sc-1398, Santa Cruz), VEGFR3 (Millipore), RPS6 (5G10, Cell Signaling), P-RPS6 (Ser240/244; #2215, Cell Signaling) and Actin (Sigma-Aldrich, A5441). HRP-conjugated secondary antibodies used were antimouse and anti-rabbit (GE Healthcare) or anti-goat (Jackson Immunoresearch).
For analyses of tissue architecture and expression of lymphangiogenic markers, tissues were fixed in formalin and embedded in paraffin. Sections were prepared for haematoxylin and eosin (H&E) staining. For immunostaining, 3 μ m paraffin sections were deparaffinized and placed in PBS. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide. Sections were incubated with blocking solution (DAKO) to reduce non-specific staining. Incubation with the indicated antibodies (see below) was then followed by staining with the appropriate biotinylated secondary antibodies (DAKO). Tissue sections were then incubated with Envision-Peroxidase Rabbit Ready-to-Use (DAKO) using diaminobenzidine (DAB) as a substrate for the peroxidase reaction. Sections were finally counterstained with haematoxylin (Anatech) and mounted with permanent mounting medium. For MDK and VEGFC histological analyses, the Ultravision ONE Detection System (RTU, Thermo Scientific) was used according to the manufacturer's instructions. For immunofluorescence-based analyses, tissue sections were deparaffinized, incubated overnight with primary antibodies at 4 °C in a humidified chamber and then rinsed and incubated with fluorescent secondary antibodies for 1 h at room temperature. Nuclei were counterstained with Prolong Gold + DAPI (Invitrogen, concentration 5 μ g ml −1 ) 20 min before imaging. Primary antibodies used were: hVEGFR3 (MAB3757, Millipore), mVegfr3 (AF743, R&D Systems), mLyve-1 (ab14917, Millipore), hLYVE-1 (ab36993, Abcam), CD-31(ab28364, Abcam), MDK (sc-1398, Santa Cruz), VEGFC (NB110-61022, NB110-61022), RPS6 (5G10, Cell Signaling), P-RPS6 (Ser240/244; #2215, Cell Signaling) CD169 (clone 3D6.112; AbD Serotec), MCSF antibody (ab183316, Abcam).
Assessment of metastatic tumour cell burden in Vegfr3
Luc mice. mCherrylabelled SK-Mel-147 melanoma cells (1 × 10 6 ) were implanted subcutaneously into 14-week old female Vegfr3
Luc nu/nu immunodeficient mice. Animals were randomized into four groups for weekly analyses and collection. At the desired times, V3-Luc emission was measured as described above. Sentinel lymph nodes and lungs were removed and samples were preserved in RNAlater (ThermoFisher, Cat. AM7020). RNA and DNA purification from tissue samples was performed using AllPrep DNA/RNA Mini Kit (Qiagen, Cat. 80204). cDNA preparations were performed using the High-Capacity cDNA Reverse Transcription Kit (ThermoFisher, Cat. 4368814). Quantification of melanoma cells was performed by qRT-PCR, using primers for mCherry and 18S as described in the qRT-PCR section. Standard curves for the estimation of cell number were performed using defined numbers of SK-Mel-147-mCherry cells. qRT-PCR. RNA purification from melanoma tissue samples and qRT-PCR were performed using the following primers: hVEGFC-F: TGCCAG CAACACTACCACAG; hVEGFC-R: GTGATTATTCCACATGTAATTGGTG; hVEGFD-F: CAAGAAAGCGGCTTCAGGTA; hVEGFD-R: GCAACGA TCTTCGTCAAACA; hVEGFR3-F: CAAGAAAGCGGCTTCAGGTA; hVEGF R3-R: GCAGAGAAGAAAATGCTGACG; MDK-F: CCTGCAACTGGA AGAAGGAG; MDK-R: CTGGCACTGAGCATTGTAGC; mCherry-F: CCCGCCGACATCCCCGACTA; mCherry-R: GGGTCACGGTCACCACGCC; 18S-F: TTGGAGGGCAAGTCTGGTG; 18S-R: CCGCTCCCAAGATCCAACTA. HLEC proliferation assay. To define the impact of MDK-overexpressing melanoma cells on the growth of HLEC, conditioned medium was collected from WM164 cells infected with control (empty vector) or MDK-expressing lentiviruses.
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Melanoma cells were cultured in DMEM supplemented with 10% FBS until they reach 80% confluence. Medium was then changed to EGM-2 MV for 24 h. This conditioned medium was collected, centrifuged for 5 min at 1,500 r.p.m. and filtered through a 0.45-μ m pore membrane before use. Conditioned medium was then added to HLEC 24 h after plating (6 well plates, 2 × 10 5 cells per well) for a 5-day analysis of proliferation rate using the Promega's CellTiter MTS cell proliferation assay kit. Conversely, analysis of growth of HLEC was performed on cells pre-conditioned with medium from SK-Mel-147 expressing shC or shMDK (1) and shMDK(5) to determine the inhibitory effects of MDK depletion. HLEC sprouting assay. HLECs were cultured in EGM-2 MV medium (Lonza). Hanging drop cultures were generated 24 h after incubation with Cell Tracker (Molecular Probes, Life Technologies), using 1,000 cells per drop (25 μ l). This was performed in EBM-2 medium containing 20% Methocel. Sphere formation was checked by microscopy 24 h thereafter. Spheres were then collected in PBS supplemented with 10% of FBS, centrifuged for 3 min at 200 r.p.m., and resuspended in the desired EGM-2 MV conditioned medium obtained as described before. When indicated, spheres were treated with 1 μ M rapamycin or 10 nM torin 1 and embedded in type I collagen. Pictures were collected 24 h thereafter. The number and length of sprouts were quantified using ImageJ software. Melanoma cell attachment and transmigration through HLEC. HLEC were seeded in a 24-well glass bottom plate and then incubated at 37 °C with 5% CO 2 . At confluence, medium was refreshed in the absence or presence of 500 μ g ml
recombinant human MDK (Peprotech) for a 16-h incubation. 10 5 mCherry labelled SK-Mel-147 or WM164 cells were then seeded on top of the pre-conditioned HLEC cells for immediate time-lapse imaging (fluorescence videomicroscopy using a wide-field microscope coupled with a CCD camera). For SK-Mel-147 cells, images were captured at 2.33-min intervals for a total of 200 min, and for WM164 every 3.33 min (total of 965.7 min). Videos were assembled using ImageJ software, which was also used to quantify melanoma cell surface (mCherry-positive areas) at the indicated acquisition times. Results are represented as the mean and s.e.m. of the fold-induction of the mCherry-covered area per frame, analysed in four different wells (n > 200 cells per time point and condition). t-test analyses were performed on time-matched observations to define statistical differences in the spreading capacity of melanoma cells on control-vs MDK-conditioned HLEC.
Transmigration analyses were performed on 8-μ m pore Boyden chambers containing confluent HLEC monolayer (preconditioned for 24 h with empty medium or with medium containing 500 μ g ml −1 recombinant human MDK). 10 5 mCherry-labelled SK-Mel-147 or WM164 cells were seeded on top of these pretreated HLEC cells using DMEM without growth factors. As a chemo-attractant, complete DMEM was added to the bottom of the plates. Cells were incubated in these conditions for 16 h and subsequently fixed in 4% paraformaldehyde. Chambers were then scanned using a Leica SP5-multiphoton confocal microscope (Leica Microsystems). The number of melanoma-mCherry cells in the upper part (non-migrating) and lower part (migrating) of the chamber was quantified using Imaris image analysis software (Bitplane). t-tests were performed on matched observations using Graphpad Prism software. Exosome purification. Exosomes were prepared essentially as described 10 . Briefly, cells were cultured in medium supplemented with 10% exosome-depleted FBS (Hyclone). FBS was depleted of bovine exosomes by ultracentrifugation at 100,000g overnight. Supernatant fractions collected from 24-h cell cultures were pelleted by centrifugation at 500g for 10 min. The supernatant was centrifuged at 20,000g for 20 min. Exosomes were then collected by centrifugation at 100,000g for 70 min. The exosome pellet was resuspended in 13 ml PBS and collected by ultracentrifugation at 100,000g for 70 min. The exosome-producing cells were trypsinized, counted and stored for proteomic analysis. ELISA-based analysis of MDK secretion. For the ELISA estimation of soluble or exosome-contained MDK, cells were incubated for 24 h in DMEM with 10% FBS before collection. The conditioned medium was then divided in two fractions, one for elimination of cell debris by centrifugation at 13,000 r.p.m. for 10 min, and another to deplete exosomes by ultracentrifugation at 100,000g for 14 h. MDK expression in these soluble and exosome-cleared conditions was analysed by ELISA (Human MIDKINE ELISA Development Kit 900-K190; Prepotech). Readings were obtained for three independent biological replicates. To define MDK concentration in exosomes, these were lysed with ELISA extraction buffer 75 mM Tris pH 7.0; 150 mM NaCl; 1 mM EGTA; 1 mM EDTA and 1% Triton 100; 0.5% sodium deoxycholate and protease and phosphatase inhibitors. LC-MS/MS analysis of exosome cargo. For exosome profiling, samples were digested using the standard filter aided sample preparation (FASP) protocol 37 . Briefly, samples were resuspended in UT buffer (8 M urea in 100 mM Tris-HCl, pH 8.01). Proteins were then reduced with 10 mM DTT and alkylated using 50 mM IAA for 20 min in the dark. Proteins were digested with Lys-C (Wako) for 6 h (1:50). Finally, samples were diluted in 50 mM ammonium bicarbonate to reduce the urea concentration to 1 M, and were subsequently digested with Trypsin (Promega; 1:100 sample concentration, overnight at 37 °C). The resulting peptides were desalted using micro-columns filled with Poros Oligo R3 beads (Life Technologies). Samples were dried and dissolved in 30 μ l 0.1% formic acid (FA). Peptides were separated by reversed-phase chromatography using a nanoLC Ultra system (Eksigent), directly coupled with a LTQ-Orbitrap Velos instrument (Thermo) via nanoESI (ProxeonBiosystem). Peptides were loaded onto a ReprosilPur C18 column (3 μ m, 400 × 0.075 mm; Dr. Maisch), with a trapping column (Prot Trap Column 0.3 × 10 mm, ReproSil C18-AQ, 5 μ m), for 10 min with a flow rate of 2.5 μ l per min loading buffer (0.1% FA). Elution was performed with a 120-min linear gradient (buffer A: 2% ACN, 0.1% FA; buffer B: 100% ACN, 0.1% FA) at 300 nl per min. Peptides were directly electrosprayed into the mass spectrometer using a PicoTip emitter (360/20 OD/ID μ m tip, ID 10 μ m, New Objective) at 1.4 kV spray voltage with a heated capillary temperature of 325 °C and S-Lens of 60%. Mass spectra were acquired in a data-dependent manner, with an automatic switch between MS and MS/MS scans using a top 10 method. MS spectra were acquired with a resolution of 60,000 (FWHM) at 400 m/z in the Orbitrap, scanning a mass range between 350 and 1500 m/z. Peptide fragmentation was performed using collision-induced dissociation (CID), set at 35%. Label-free quantification was performed in MaxQuant (1.5.1.2) using default settings and further statistical analysis of the quantitative data was conducted with Perseus (1.5.1.6). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD002703. The proteomic analysis resulted in the identification and quantification of a total of 1,705 exosomal proteins (Fig. 3a) . A statistical filter (cut-off of FDR 0.05 and a threshold S0 of 0.8) was applied to identify factors enriched with respect to the non-metastatic and non-lymphangiogenic WM164. A second filter was used to eliminate factors shared with cell line WM35 (with lymphangiogenesis restricted mostly to cutaneous lesions). This approach identified 139, 180 and 188 candidates for long range-acting metastatic factors in 451LU, SK-Mel-28 and SK-Mel-147 cells, respectively, as summarized in Fig. 3b (Supplementary Table 2) . The top 20% of these proteins were then scored on the basis of three criteria: (i) being common to all cell lines that activate distal lymphangiogenesis, (ii) having described functions associated with metastasis but not previously linked to lymphangiogenesis, and (iii) being understudied in melanoma. The highest ranked protein in this analysis was MDK (Fig. 3b) . RNA-seq and bioinformatic analyses. RNA-seq was performed by the CNIO Genomics Unit. One microgram of total RNA from the samples was used. The average sample RNA Integrity Number was 9.75 (Agilent 2100 Bioanalyzer). The poly(A) + fraction was purified and randomly fragmented, converted to double-stranded cDNA and processed through subsequent enzymatic treatments of end-repair, dA-tailing, and ligation to adapters as in Illumina's TruSeq Stranded mRNA Sample Preparation Part # 15031047 Rev. D kit (this kit incorporates dUTP during 2nd strand cDNA synthesis, which implies that only the cDNA strand generated during 1st strand synthesis is eventually sequenced). The adapterligated library was completed by PCR with Illumina PE primers (eight cycles). The resulting purified cDNA library was applied to an Illumina flow cell for cluster generation and sequenced on an Illumina HiSeq 2500 following the manufacturer's protocols. Fifty-base-pair single-end sequenced reads were analysed with the nextpresso pipeline (http://bioinfo.cnio.es/nextpresso/), as follows: sequencing quality was checked with FastQC v0.11.0 (http://www. bioinformatics.babraham. ac.uk/projects/fastqc/). Reads were aligned to the human genome (GRCh37/ hg19) with TopHat-2.0.10 38 using Bowtie 1.0.0 39 and Samtools 0.1.19 40 , allowing 2 mismatches and 20 multihits. Transcript quantification and differential expression were calculated with Cufflinks 2.2.1 38 , using the human GRCh37/hg19 transcript annotations from https://ccb.jhu.edu/software/tophat/igenomes. shtml. GSEAPreranked 41 was used to perform gene set enrichment analysis of the described gene signatures on a pre-ranked gene list, setting 1,000 gene set permutations. Only those gene sets with significant enrichment levels (FDR q < 0.25) were finally considered. Intravital multiphoton microscopy. SK-Mel-147 cells labelled with GFP and transduced with control shRNA (shC) or MDK shRNA(5) were injected subcutaneously (1 × 10 6 cells) into 6-week-old female nude mice. Intravital imaging of the inguinal lymph node adjacent to the tumour was performed 3 weeks after tumour cell injection. To label the inguinal lymph node, 20 μ l of 155 kDa TRITCdextran was injected intradermally at the lateral tail base on the tumour side. Mice were anaesthetized with 5% isofluorane and the lymph node was exposed by skin flap surgery as previously described 42 . Imaging was performed using an Olympus FV1000 multiphoton microscope with a 25× 1.05 NA water immersion objective as previously described 43 and adapted for the lymph node. Specifically, we focused on the subcapsular sinus, the outer area of lymph nodes that serves as a main barrier to tumour cell entry 30, 44 . Briefly, a Coherent Chameleon Vision II laser was tuned to 880 nm for excitation of GFP and TRITC-dextran. Collagen was visualized by second harmonic generation. 3D images were reconstructed with
Imaris (Bitplane). 4D images were acquired at a 5-μ m step-size ranging from 100 to 150 μ m in depth from the lymph node surface with a 2-min time interval for 30 min. Individual Z-slices are provided at different time points in Extended Data Fig. 8c (three different planes containing the cell volume, starting at 20 μ m depth from lymph node capsule with 5 μ m step size) showing no Z-drift. Orthogonal Z-Y views are also provided to visualize the 3D location of the cell in relation to the lymphatic vessel over time. Images were analysed in ImageJ.
As shown in Extended Data Fig. 8a (upper panels), MDK-expressing SK-Mel-147 cells were found in clusters invading the subcapsular sinus at sites of a large expansion of the vasculature (see dextran-labelled areas). This was in contrast to individual or small cell clusters of MDK-deficient SK-Mel-147 cells found blocked at the border of the subcapsular sinus on the collagen-enriched area (Extended Data Fig. 8a, bottom panels) . Snap shots in Extended Data  Fig. 8b, c further illustrate the impact of MDK deficiency on the ability of melanoma cells to move towards the vasculature. Therefore, these data provide additional mechanistic explanation as to why modulating the endogenous levels of MDK in melanoma cell lines affects not only their pro-lymphangiogenic capability, but also their metastatic potential. MDK expression and metastatic risk in human clinical biopsies. MDK levels were estimated by two independent pathologists. Lymph node and paraffinembedded blocks were collected from a retrospective series of 62 patients with melanoma (21-85 years old, with a median age of 65; stage II-III at diagnosis). Gender distribution was 66.1% female and 33.9% male. Immunohistochemistry was performed in 3-μ m sections of primary lesions or sentinel lymph nodes as indicated and MDK-specific staining was scored as negative, low or high taking into account the intensity of its expression. Survival curves were estimated with the Kaplan-Meier product-limit method and compared using log-rank test. Hazard ratios were calculated using Cox regression and adjusted with univariate and multivariate models for Breslow depth, age or gender. DFS was defined as the time interval between diagnosis and the development of the earliest metastasis detected at any anatomical site. DFS was considered censored for patients who did not present metastases at the last follow-up. Human tumour biopsies were obtained from the i+ 12 Biobank (RD09/0076/00118) of the Hospital 12 Octubre, the biobank from the Hospital Clínic de Barcelona, and the Spanish National Biobank Network, with the corresponding informed consent and ethical protocols approved by their Clinical Investigation Ethical Committees. Statistical analyses. Cell proliferation and tumour growth curves were analysed by one-way and two-way ANOVA with Dunnett's multiple comparison test (mixed model) considering matching among the measures at different time points. P values are indicated in each figure for statistically significant comparisons (P < 0.05). For the analysis of proteomic data, LFQ values were log 2 transformed and missing data were imputed based on the observed normal distributions (width value 0.3 and down-shift 2). Then, a two-sample Student's test was performed using the following settings and filters in Perseus software: 250 randomizations, FDR = 0.05 and fudge factor S0 = 0.8. For simplicity, only significant P values are shown in all experiments. Data availability. The mass spectrometry proteomics data have been deposited in the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD002703 (http://proteomecentral.proteomexchange.org/cgi/ GetDataset?ID= PXD002703). RNA-seq data have been deposited in NCBI's Gene Expression Omnibus with accession number GSE94549. Source Data are provided for Figs 1e, 2a, b and 3e-l and Extended Data Figs 1d, 2d-f, 3b-e, 4a, 5a, c-i, 6b -e, 7a, c, e and 9a, b. All other data that support the findings of this study are available from the authors upon reasonable request. 
